Drug intelligence / Profile preview

DWRX5007

Development stage: Preclinical
Lead developer: Daewoong Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal, Transdermal

Overview

DWRX5007 is a trivalent or quadrivalent influenza vaccine candidate being developed by Daewoong Therapeutics. Formulated for delivery via a microneedle patch, the vaccine utilizes the company's proprietary drug delivery technology to provide a painless, self-administered, and room-temperature stable alternative to traditional injectable flu vaccines. It is designed to induce a protective immune response against influenza virus antigens. The candidate is currently in preclinical development.

Other names: Quadrivalent Influenza VaccineTrivalent Influenza Vaccine

Targets

HA0 (Influenza B virus hemagglutinin)

Beyond the preview

Go deeper on DWRX5007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWRX5007.

Explore the full profile